优先治疗肥胖症:扩大心脏病专家的作用,改善心血管健康和预后。

IF 1.3 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS
Cardiovascular Endocrinology & Metabolism Pub Date : 2023-02-07 eCollection Date: 2023-03-01 DOI:10.1097/XCE.0000000000000279
Donna H Ryan, John E Deanfield, Stephan Jacob
{"title":"优先治疗肥胖症:扩大心脏病专家的作用,改善心血管健康和预后。","authors":"Donna H Ryan, John E Deanfield, Stephan Jacob","doi":"10.1097/XCE.0000000000000279","DOIUrl":null,"url":null,"abstract":"<p><p>Obesity is a major risk factor for cardiovascular disease, yet management remains poor. Cardiologists and healthcare professionals treating people with high cardiovascular risk are in a position to address overweight and obesity to improve cardiovascular health. There are several treatment options for obesity, which are associated with numerous health benefits. Modest weight reductions of 5-10% improve cardiovascular risk factors, with greater weight loss bringing about greater benefits. Anti-obesity medications can support weight reduction when lifestyle modifications alone are insufficient. The weight loss induced by these treatments can improve cardiovascular risk, and some therapies - such as glucagon-like-peptide-1 analogues - may promote these benefits independently of weight loss. Bariatric surgery can induce greater weight losses than other treatment modalities and is associated with numerous health benefits, but newer medications such as semaglutide and those in development, such as tirzepatide, produce robust weight loss efficacy that is approaching that of bariatric surgery. Healthcare professionals must approach this disease with compassion and collaborate with patients to develop sustainable plans that improve health and maintain weight loss over the long term.</p>","PeriodicalId":43231,"journal":{"name":"Cardiovascular Endocrinology & Metabolism","volume":"12 1","pages":"e0279"},"PeriodicalIF":1.3000,"publicationDate":"2023-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/1f/28/xce-12-e0279.PMC9911203.pdf","citationCount":"0","resultStr":"{\"title\":\"Prioritizing obesity treatment: expanding the role of cardiologists to improve cardiovascular health and outcomes.\",\"authors\":\"Donna H Ryan, John E Deanfield, Stephan Jacob\",\"doi\":\"10.1097/XCE.0000000000000279\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Obesity is a major risk factor for cardiovascular disease, yet management remains poor. Cardiologists and healthcare professionals treating people with high cardiovascular risk are in a position to address overweight and obesity to improve cardiovascular health. There are several treatment options for obesity, which are associated with numerous health benefits. Modest weight reductions of 5-10% improve cardiovascular risk factors, with greater weight loss bringing about greater benefits. Anti-obesity medications can support weight reduction when lifestyle modifications alone are insufficient. The weight loss induced by these treatments can improve cardiovascular risk, and some therapies - such as glucagon-like-peptide-1 analogues - may promote these benefits independently of weight loss. Bariatric surgery can induce greater weight losses than other treatment modalities and is associated with numerous health benefits, but newer medications such as semaglutide and those in development, such as tirzepatide, produce robust weight loss efficacy that is approaching that of bariatric surgery. Healthcare professionals must approach this disease with compassion and collaborate with patients to develop sustainable plans that improve health and maintain weight loss over the long term.</p>\",\"PeriodicalId\":43231,\"journal\":{\"name\":\"Cardiovascular Endocrinology & Metabolism\",\"volume\":\"12 1\",\"pages\":\"e0279\"},\"PeriodicalIF\":1.3000,\"publicationDate\":\"2023-02-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/1f/28/xce-12-e0279.PMC9911203.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cardiovascular Endocrinology & Metabolism\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1097/XCE.0000000000000279\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/3/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular Endocrinology & Metabolism","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/XCE.0000000000000279","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/3/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

摘要

肥胖是心血管疾病的一个主要风险因素,但管理不善。心脏病专家和医护人员在治疗心血管疾病高危人群时,有能力解决超重和肥胖问题,以改善心血管健康。目前有多种治疗肥胖症的方法,可为健康带来诸多益处。适度减轻 5-10% 的体重可改善心血管风险因素,减轻更多体重可带来更多益处。如果仅靠改变生活方式不足以减轻体重,抗肥胖药物可以帮助减轻体重。这些治疗方法所引起的体重减轻可改善心血管风险,有些疗法(如胰高血糖素样肽-1 类似物)可在减轻体重的同时促进这些益处。与其他治疗方式相比,减重手术能使体重减轻更多,并能带来许多健康益处,但较新的药物,如塞马鲁肽和正在研发中的药物,如替泽帕肽,能产生接近减重手术的强大减重疗效。医护人员必须以同情的态度对待这种疾病,并与患者合作制定可持续的计划,以改善健康状况并长期保持减肥效果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Prioritizing obesity treatment: expanding the role of cardiologists to improve cardiovascular health and outcomes.

Prioritizing obesity treatment: expanding the role of cardiologists to improve cardiovascular health and outcomes.

Prioritizing obesity treatment: expanding the role of cardiologists to improve cardiovascular health and outcomes.

Obesity is a major risk factor for cardiovascular disease, yet management remains poor. Cardiologists and healthcare professionals treating people with high cardiovascular risk are in a position to address overweight and obesity to improve cardiovascular health. There are several treatment options for obesity, which are associated with numerous health benefits. Modest weight reductions of 5-10% improve cardiovascular risk factors, with greater weight loss bringing about greater benefits. Anti-obesity medications can support weight reduction when lifestyle modifications alone are insufficient. The weight loss induced by these treatments can improve cardiovascular risk, and some therapies - such as glucagon-like-peptide-1 analogues - may promote these benefits independently of weight loss. Bariatric surgery can induce greater weight losses than other treatment modalities and is associated with numerous health benefits, but newer medications such as semaglutide and those in development, such as tirzepatide, produce robust weight loss efficacy that is approaching that of bariatric surgery. Healthcare professionals must approach this disease with compassion and collaborate with patients to develop sustainable plans that improve health and maintain weight loss over the long term.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Cardiovascular Endocrinology & Metabolism
Cardiovascular Endocrinology & Metabolism CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
5.60
自引率
0.00%
发文量
24
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信